Bupropion-imipramine

From Psychiatrienet
Revision as of 14:35, 27 November 2009 by Mariska (talk | contribs)
Jump to: navigation, search
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine

Switch medication from bupropion to imipramine.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Before day 1: Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
  • Day 1: Stop administration of bupropion
Eenrichtingbord.png Start imipramine
  • Day 1-3: start administration of imipramine the next day in a low dosage of 25 mg/day.
  • Day 4: increase dosage of imipramine to 50 mg/day and continue slowly increasing the dosage depending on the condition of the patient.
Infobord.png More information
  • Bupropion slows the metabolism of imipramine via CYP2D6.
  • Caution is necessary at the start of administration of imipramine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.